Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis Patients
Sponsor: Massachusetts General Hospital
This PHASE1 trial investigates Lung Cancer and Pulmonary Fibrosis and is currently actively recruiting participants. Massachusetts General Hospital leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Feb 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Jul 2022 — Jan 2024 [monthly]
Recruiting PHASE1
-
Apr 2021 — Jul 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Oct 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Sep 2018 — Sep 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .